Skip to main content
Media RelationsInvestor RelationsHome
Logo SphingotecLogo Sphingotec

Investor Relations

We aim to sustain continuous, clear, and trustful communication with all our partners and stakeholders.

Innovative diagnostic solutions for acute and critical care conditions

We are committed to improving patient outcomes with innovative diagnostic solutions for acute and critical care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.

SphingoTec develops and markets innovative IVD solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements to routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such as sepsis, acute heart failure, and acute kidney injury.

SphingoTec is a privately held company with a long history of biomarker discovery, development and validation. We are the legal manufacturer of the CE IVD microtiter plate assays. Committed to providing solutions that meet and exceed customer and regulatory requirements, we manufacture our products in accordance with EN ISO 13485:2016.

 

Our investors share our vision of improving patient outcomes

Working medical staff in intensive care unit.

SphingoTec in a nutshell

Our portfolio of tests supports better management of critically ill patients, where fast and reliable information is essential in taking treatment decisions. The solutions we have created combine scientific discoveries with medical research and robust technologies to support clinicians in improving disease management. We work together with internationally leading academic and non-academic medical centers, as well as with global IVD and pharma companies to bring these innovations closer to the patients. 

Investment Thesis

Global expansion

Through strategic partnerships and out-licensing of our biomarkers, we aim at making the innovations worldwide available.

Early stage opportunity

An opportunity of investment in more than 200 patents that could benefit over 60 million patients worldwide.

Skillful team

A skilled international team with a broad scope of experience committed to improve patient lives

An innovative portfolio

Innovative biomarkers for diagnosis, outcome prediction, and monitoring of mortality drivers in the intensive care unit.

Latest News

View all News

06. September 2023

International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

A new study and real-world data on the kidney function biomarker penKid underline its potential to monitor kidney function during acute kidney injury (AKI) and RRT and to support liberation decisions from RRT.
Read more
31. August 2023

Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid

The MDA solidifies the partnership between Boditech and SphingoTec, aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS platforms.
Read more
09. May 2023

SphingoTec's Innovative IVD Product sphingotest® penKid® Receives First IVDR Certificate

SphingoTec has been successfully re-certified according to ISO 13485 and received its first IVDR certificate for its IVD product sphingotest® penKid®.
Read more

Events & Expos

View all Events

29. November - 01. December 2023

14:59 - 15:00

Hamburg, Germany

23. Kongress der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI)

The DIVI is the largest event for emergency and intensive care medicine in German-speaking countries.
Read more
09. - 11. November 2023

13:07 - 13:08

Berndorf, Österreich

42. Hernsteiner Fortbildungstagung

This conference will explore the theme of "Stress & Coping - Cell Organ Human Team Society," featuring a diverse range of practical and scientific content.
Read more
05. - 08. October 2023

14:04 - 15:05

Berlin, Germany

Kongress für Nephrologie 2023

The Forum Nephrologie is a scientific, educational, and networking meeting and part of the 15. Jahrestagung der DGfN. The main congress program will kick off with an opening ceremony on Thursday,…

Read more

Contact Investor Relations

Do you have any questions or require more information? Please contact the Investor Relations Team, send us an e-mail or call us.

phone: + 49 (0)330 220 56 5 - 0
email: ir@sphingotec.com

Dr. Angelo Moesslang

Chief Financial Officer and Managing Director

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now